Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03594175 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality
A Phase 3 study, sponsored by Chiesi Farmaceutici S.p.A..
- Terminated
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT03594175 is a Phase 3 study that was terminated before completion, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 462 participants.
The verdict
NCT03594175, a Phase 3 study, was terminated before completion, sponsored by Chiesi Farmaceutici S.p.A..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
Interventions
- DRUG Placebo
- DRUG Alteplase
- DRUG CUSA-081
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03594175
The ClinicalTrials.gov registry entry for NCT03594175 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03594175 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03594175 about?
NCT03594175 is a clinical study titled "Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality". To evaluate the efficacy and safety of CUSA-081 (diluted reteplase) in the restoration of central venous access device (CVAD) functionality in participants 18 years and older.
What is the current status of trial NCT03594175?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2020-02-12. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT03594175?
The interventions under investigation include: Placebo (DRUG), Alteplase (DRUG), CUSA-081 (DRUG).
Who is sponsoring clinical trial NCT03594175?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.